Bristol-Myers completing enrollment in OCTAVE study

BMY said it will complete enrollment this week of its 25,000-patient international Phase III Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) trial comparing its Vanlev omapat...